Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.
Deaths from HIV/AIDS are ten times lower than at the peak of the epidemic, and new research could drive that down even more.
The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...
A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond to prior vaccination.
The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
Globally, an estimated 40 million people live with HIV. Although 30·7 million of the people living with HIV have access to antiretroviral therapy, there were still 1·3 million new infections in 2022.1 ...
The confirmation of Malawi’s first Covid-19 case on April 2 2020 left Fatima Moda terrified. Day and night, radio stations ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond to prior vaccination, ...
HIV Vaccine Trials Network external relations program manager Dr. Daniel Driffin spoke at the 2024 White House World AIDS Day ...
The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback